GlassScriptPhysician profile
Monique M Monteilh
NPI 1013917533
$3,342.49
in general payments reported to CMS, 2019-2025
30 companies · $558 in 2025
The $558 reported for 2025 was more than what 83% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $165 · 2021: $395 · 2022: $836 · 2023: $802 · 2024: $357 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,518 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,518.25 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $632.13 | 2019-2023 | |
| Astellas Pharma US INC | $511.31 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $301.37 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $257.67 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $152.12 | 2019-2025 | |
| Avion Pharmaceuticals | $144.63 | 2019-2023 | Balcoltra |
| Intuitive Surgical, INC. | $124.08 | 2022 | |
| Daiichi Sankyo INC. | $116.64 | 2020-2023 | Injectafer |
| Biohaven Pharmaceuticals, INC. | $111.73 | 2021 | |
| Hologic Sales and Service, LLC | $104.05 | 2019-2024 | Aptima |
| Exeltis, USA INC. | $94.88 | 2021-2023 | Slynd |
| Organon LLC | $93.62 | 2022-2025 | Nexplanon |
| Becton, Dickinson and Company | $90.96 | 2023-2024 | Bd Max System, Bd Max Instrument |
| Sage Therapeutics, LLC | $80.47 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $78.58 | 2025 | Ally II Ups, Endosee |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $69.85 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $58.98 | 2019-2021 | |
| Amgen INC. | $55.39 | 2019-2022 | |
| Therapeuticsmd, INC. | $51.27 | 2022 | |
| Mylan Pharmaceuticals INC. | $48.21 | 2019-2022 | |
| Myovant Sciences INC. | $32.49 | 2022 | |
| Next Science LLC | $21.59 | 2020 | |
| Alfasigma USA, INC. | $19.30 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.71 | 2025 | Qelbree |
| Millicent US INC | $13.27 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.98 | 2022 | |
| Ferring Pharmaceuticals INC. | $12.69 | 2019 | |
| Currax Pharmaceuticals LLC | $11.77 | 2022 | |
| Amag Pharmaceuticals, INC. | $11.50 | 2019 | |
| Virtus Pharmaceuticals LLC | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Monteilh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.